Overview

Safety of Larazotide Acetate in Healthy Volunteers

Status:
Completed
Trial end date:
2006-02-27
Target enrollment:
0
Participant gender:
All
Summary
To demonstrate the safety, tolerance and pharmacokinetics of multiple, oral doses of larazotide acetate.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
9 Meters Biopharma, Inc.
Alba Therapeutics
Criteria
Inclusion Criteria:

- Healthy male and female subjects

- BMI between 18 and 30.

Exclusion Criteria:

- Subjects with clinically significant abnormal clinical lab results

- Hemoglobin < 12g/dL

- Subjects with diarrhea within 3 days prior to treatment visit